Clinical efficacy of Seretid in COPD patients. From findings of the TRISTAN trial

1. Barnes P.J., Pedersen S., Busse W.W. Efficacy and safety of inhaled corticosteroids Am. J. Respir. Crit. Care Med. 1998; 157: s51-s53.

2. Barnes P.J. Novel approaches and targets for treatment of chronic obstructive pulmonary disease. Ibid. 1999; 160 (5): S72-S79.

3. Cazzola М., Lorenzo G.D., Perna F.D. et al. Additive effects of salmeterol and fluticasone or theophylline in COPD. Chest 2000; 118: 1576-1581.

4. Global initiative for chronic obstructive lung disease. National Heart, Lung, and Blood Institute, NIH and World Health Organization. Executive summary. Bethesda; 2000.

5. NHLBI/WHO Workshop report: Global strategy for asthma management and prevention. NIH publication № 02-3659. Bethesda; 2002. 1-177.

6. Postma D.S., Kerstjens H.A.M. Are inhaled glucocorticosteroids effective in chronic obstructive pulmonary disease? Am. J. Respir. Crit. Care Med. 1999; 160: S66-S71.

7. Shrewsbury S., Pyke S., Britton M. Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA). Br. Med. J. 2000; 320: 1368-1379.

8. TRISTAN COPD study. TRISTAN COPD Newsletter 09.10.2001; 1-21.